These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23138905)

  • 1. The enhanced pre- and postnatal development study for monoclonal antibodies.
    Weinbauer GF; Luft J; Fuchs A
    Methods Mol Biol; 2013; 947():185-200. PubMed ID: 23138905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The enhanced pre- and postnatal study for nonhuman primates: update and perspectives.
    Weinbauer GF; Fuchs A; Niehaus M; Luetjens CM
    Birth Defects Res C Embryo Today; 2011 Dec; 93(4):324-33. PubMed ID: 22271681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Embryo fetal development studies in nonhuman primates.
    Fuchs A; Buse E; Weinbauer GF
    Methods Mol Biol; 2013; 947():169-83. PubMed ID: 23138904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developmental toxicity testing of monoclonal antibodies: an enhanced pre- and postnatal study design option.
    Stewart J
    Reprod Toxicol; 2009 Sep; 28(2):220-5. PubMed ID: 19379807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre- and postnatal development in the cynomolgus monkey following administration of ABT-874, a human anti-IL-12/23p40 monoclonal antibody.
    Enright BP; Tornesi B; Weinbauer GF; Blaich G
    Birth Defects Res B Dev Reprod Toxicol; 2012 Dec; 95(6):431-43. PubMed ID: 23212752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation.
    Martin PL; Sachs C; Imai N; Tsusaki H; Oneda S; Jiao Q; Treacy G
    Birth Defects Res B Dev Reprod Toxicol; 2010 Oct; 89(5):351-63. PubMed ID: 20540088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Object discrimination reversal as a method to assess cognitive impairment in nonhuman primate enhanced pre- and postnatal developmental (ePPND) studies: statistical power analysis.
    Cappon GD; Bowman CJ; Hurtt ME; Grantham LE
    Birth Defects Res B Dev Reprod Toxicol; 2012 Oct; 95(5):354-62. PubMed ID: 22930561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys.
    Vaidyanathan A; McKeever K; Anand B; Eppler S; Weinbauer GF; Beyer JC
    Toxicol Sci; 2011 Jan; 119(1):116-25. PubMed ID: 20937725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cynomolgus monkey as a model for developmental toxicity studies: variability of pregnancy losses, statistical power estimates, and group size considerations.
    Jarvis P; Srivastav S; Vogelwedde E; Stewart J; Mitchard T; Weinbauer GF
    Birth Defects Res B Dev Reprod Toxicol; 2010 Jun; 89(3):175-87. PubMed ID: 20544806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Group size experiences with enhanced pre- and postnatal development studies in the long-tailed macaque (
    Luetjens CM; Fuchs A; Baker A; Weinbauer GF
    Primate Biol; 2020; 7(1):1-4. PubMed ID: 32232119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of SA237, a humanized anti-interleukin-6 receptor monoclonal antibody, on pre- and postnatal development in cynomolgus monkey.
    Katagiri R; Ishihara-Hattori K; Frings W; Amano J; Fuchs A; Chiba S
    Birth Defects Res; 2017 Jul; 109(11):843-856. PubMed ID: 28504465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmental toxicity testing of vaccines.
    Barrow PC; Allais L
    Methods Mol Biol; 2013; 947():81-9. PubMed ID: 23138897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor.
    Wehner NG; Shopp G; Oneda S; Clarke J
    Birth Defects Res B Dev Reprod Toxicol; 2009 Apr; 86(2):117-30. PubMed ID: 19278014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developmental and reproductive toxicology studies in nonhuman primates.
    Chellman GJ; Bussiere JL; Makori N; Martin PL; Ooshima Y; Weinbauer GF
    Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):446-62. PubMed ID: 20025046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced normograms and pregnancy outcome analysis in nonhuman primate developmental toxicity studies.
    Grossmann H; Weinbauer GF; Baker A; Fuchs A; Luetjens CM
    Reprod Toxicol; 2020 Aug; 95():29-36. PubMed ID: 32413491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The developmental toxicity testing of biologics.
    Hazelden KP
    Methods Mol Biol; 2013; 947():31-6. PubMed ID: 23138893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ICH S5(R2) guideline for the testing of medicinal agents.
    Wise LD
    Methods Mol Biol; 2013; 947():1-11. PubMed ID: 23138891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of barusiban in a novel study design for evaluation of tocolytic agents in pregnant and neonatal monkeys, including behavioural and immunological endpoints.
    Rasmussen AD; Nelson JK; Chellman GJ; Golub M; McAnulty PA
    Reprod Toxicol; 2007 Jun; 23(4):471-9. PubMed ID: 17337159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor.
    Wehner NG; Shopp G; Osterburg I; Fuchs A; Buse E; Clarke J
    Birth Defects Res B Dev Reprod Toxicol; 2009 Apr; 86(2):144-56. PubMed ID: 19283860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of embryo-fetal developmental toxicity studies performed for recent FDA-approved pharmaceuticals.
    Ishihara-Hattori K; Barrow P
    Reprod Toxicol; 2016 Sep; 64():98-104. PubMed ID: 27112525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.